Cargando…

Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil

BACKGROUND: Visceral leishmaniasis (VL) is a zoonotic disease caused by Leishmania infantum, for which dogs constitute the main urban parasite reservoir. Control measures and the treatment of canine visceral leishmaniasis (CVL) are essential to reduce VL cases. Early and accurate detection of L. inf...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jesus, Matheus Silva, Cruz, João Victor Andrade, Coelho, Lívia Brito, Borja, Lairton Souza, da Silva, Edmilson Domingos, Solcà, Manuela da Silva, Brodskyn, Claudia Ida, Fraga, Deborah Bittencourt Mothé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359089/
https://www.ncbi.nlm.nih.gov/pubmed/34384487
http://dx.doi.org/10.1186/s13071-021-04895-z
_version_ 1783737471559794688
author de Jesus, Matheus Silva
Cruz, João Victor Andrade
Coelho, Lívia Brito
Borja, Lairton Souza
da Silva, Edmilson Domingos
Solcà, Manuela da Silva
Brodskyn, Claudia Ida
Fraga, Deborah Bittencourt Mothé
author_facet de Jesus, Matheus Silva
Cruz, João Victor Andrade
Coelho, Lívia Brito
Borja, Lairton Souza
da Silva, Edmilson Domingos
Solcà, Manuela da Silva
Brodskyn, Claudia Ida
Fraga, Deborah Bittencourt Mothé
author_sort de Jesus, Matheus Silva
collection PubMed
description BACKGROUND: Visceral leishmaniasis (VL) is a zoonotic disease caused by Leishmania infantum, for which dogs constitute the main urban parasite reservoir. Control measures and the treatment of canine visceral leishmaniasis (CVL) are essential to reduce VL cases. Early and accurate detection of L. infantum-infected dogs is crucial to the success of VL control. To improve the serological detection of L. infantum-exposed dogs, we evaluated the early diagnosis capacity of a recombinant protein (rLci5) in an immunosorbent assay (ELISA) to detect naturally infected dogs. Additionally, we evaluated the persistence of the positive results obtained by rLci5 ELISA in comparison to other conventional diagnostic test methods. METHODS: Serum samples obtained from 48 L. infantum-infected dogs involved in a cohort study were evaluated using different diagnostic methods (qPCR, EIE-LVC, DPP-LVC and splenic culture). The results were compared to rLci5 ELISA to determine its capacity to diagnose L. infantum infection at earlier infection time points. The persistence of positive diagnostic test results was also compared for each dog evaluated. RESULTS: rLci5 ELISA presented higher rates of positive results at early time points compared to the other diagnostic tests employed in the cohort study, as early as 24 months prior to detection by other tests. rLci5 ELISA positivity was 52.1% (25/48) at baseline, while qPCR was 35.4% (17/48), DPP-LVC 27.1% (13/48), EIE-LVC 22.9% (11/48) and culture only 4.2% (2/48). In at least one of the time points of the 24-month cohort study, rLci5 ELISA was positive in 100% (48/48) of the dogs, versus 83% (40/48) for qPCR, 75% (36/48) for DPP-LVC, 65% (31/48) for EIE-LVC and 31% (15/48) for culture. Investigating clinical signs in association with diagnostic test positivity, rLci5 ELISA successfully detected CVL in 62.9% (95/151) of the clinical evaluations with a score of 0–3, 64.3% (45/70) with scores between 4 and 7, and 73.7% (14/19) with scores > 7, providing higher rates of positivity than all other methods evaluated. Moreover, rLci5 ELISA presented the greatest persistence with respect to test positivity: 45.8% of the dogs evaluated. CONCLUSION: Four diagnostic tests were compared to rLci5 ELISA, which presented earlier infection diagnosis and a greater persistence of positive test results. Accordingly, the use of the rLci5 ELISA can improve CVL diagnostic performance by detecting infected dogs sooner than other testing methods, with enhanced persistence of positive results over the course of the infection. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-021-04895-z.
format Online
Article
Text
id pubmed-8359089
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83590892021-08-16 Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil de Jesus, Matheus Silva Cruz, João Victor Andrade Coelho, Lívia Brito Borja, Lairton Souza da Silva, Edmilson Domingos Solcà, Manuela da Silva Brodskyn, Claudia Ida Fraga, Deborah Bittencourt Mothé Parasit Vectors Research BACKGROUND: Visceral leishmaniasis (VL) is a zoonotic disease caused by Leishmania infantum, for which dogs constitute the main urban parasite reservoir. Control measures and the treatment of canine visceral leishmaniasis (CVL) are essential to reduce VL cases. Early and accurate detection of L. infantum-infected dogs is crucial to the success of VL control. To improve the serological detection of L. infantum-exposed dogs, we evaluated the early diagnosis capacity of a recombinant protein (rLci5) in an immunosorbent assay (ELISA) to detect naturally infected dogs. Additionally, we evaluated the persistence of the positive results obtained by rLci5 ELISA in comparison to other conventional diagnostic test methods. METHODS: Serum samples obtained from 48 L. infantum-infected dogs involved in a cohort study were evaluated using different diagnostic methods (qPCR, EIE-LVC, DPP-LVC and splenic culture). The results were compared to rLci5 ELISA to determine its capacity to diagnose L. infantum infection at earlier infection time points. The persistence of positive diagnostic test results was also compared for each dog evaluated. RESULTS: rLci5 ELISA presented higher rates of positive results at early time points compared to the other diagnostic tests employed in the cohort study, as early as 24 months prior to detection by other tests. rLci5 ELISA positivity was 52.1% (25/48) at baseline, while qPCR was 35.4% (17/48), DPP-LVC 27.1% (13/48), EIE-LVC 22.9% (11/48) and culture only 4.2% (2/48). In at least one of the time points of the 24-month cohort study, rLci5 ELISA was positive in 100% (48/48) of the dogs, versus 83% (40/48) for qPCR, 75% (36/48) for DPP-LVC, 65% (31/48) for EIE-LVC and 31% (15/48) for culture. Investigating clinical signs in association with diagnostic test positivity, rLci5 ELISA successfully detected CVL in 62.9% (95/151) of the clinical evaluations with a score of 0–3, 64.3% (45/70) with scores between 4 and 7, and 73.7% (14/19) with scores > 7, providing higher rates of positivity than all other methods evaluated. Moreover, rLci5 ELISA presented the greatest persistence with respect to test positivity: 45.8% of the dogs evaluated. CONCLUSION: Four diagnostic tests were compared to rLci5 ELISA, which presented earlier infection diagnosis and a greater persistence of positive test results. Accordingly, the use of the rLci5 ELISA can improve CVL diagnostic performance by detecting infected dogs sooner than other testing methods, with enhanced persistence of positive results over the course of the infection. GRAPHIC ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-021-04895-z. BioMed Central 2021-08-12 /pmc/articles/PMC8359089/ /pubmed/34384487 http://dx.doi.org/10.1186/s13071-021-04895-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
de Jesus, Matheus Silva
Cruz, João Victor Andrade
Coelho, Lívia Brito
Borja, Lairton Souza
da Silva, Edmilson Domingos
Solcà, Manuela da Silva
Brodskyn, Claudia Ida
Fraga, Deborah Bittencourt Mothé
Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title_full Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title_fullStr Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title_full_unstemmed Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title_short Early detection and persistent positivity of anti-Leishmania antibodies using a recombinant protein-based ELISA in naturally infected dogs in Brazil
title_sort early detection and persistent positivity of anti-leishmania antibodies using a recombinant protein-based elisa in naturally infected dogs in brazil
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359089/
https://www.ncbi.nlm.nih.gov/pubmed/34384487
http://dx.doi.org/10.1186/s13071-021-04895-z
work_keys_str_mv AT dejesusmatheussilva earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT cruzjoaovictorandrade earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT coelholiviabrito earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT borjalairtonsouza earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT dasilvaedmilsondomingos earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT solcamanueladasilva earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT brodskynclaudiaida earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil
AT fragadeborahbittencourtmothe earlydetectionandpersistentpositivityofantileishmaniaantibodiesusingarecombinantproteinbasedelisainnaturallyinfecteddogsinbrazil